Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ketamine's brain impact revealed in small stanford study

NCT ID NCT03475277

Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Stanford study looked at how ketamine changes activity in brain areas linked to reward and risk. Thirteen healthy adults who had used ketamine before underwent brain scans while performing tasks. The goal was to understand ketamine's effects on brain circuits, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ketamine
What this could lead to
If successful, this could help explain how ketamine alters brain reward pathways, potentially guiding future treatments for addiction or mood disorders.
What could go wrong
This is a very small, early biomarker study with only 13 healthy participants, so results may not apply to broader populations or lead directly to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

13 people

The number who actually took part.

Started

Aug 2019

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers with prior exposure to ketamine

Ages

18 to 55 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 18-55 years * At least 2 prior uses of ketamine when aged 18+ * BMI within healthy range (18-30) * Ability to speak, read, or understand English Exclusion Criteria: * Current active suicide ideation or history of suicide attempts * Current mood, anxiety, eating, psychotic, or substance use disorder * Lifetime psychotic or bipolar disorder * Schizophrenia in a first degree relative * Current use of psychotropic medication * Prior adverse ketamine response * Allergy or hypersensitivity to ketamine * Use of ketamine in past 7 days * Cannabis use in the past 7 days, illicit recreational drug use in the 48 hours prior to sessions, and/or alcohol use in the 24 hours prior to sessions * Concurrent use of any medications that might increase the risk of participation (e.g., drug interactions) * History of epilepsy, convulsions, seizures, LOC \>10 min * Renal/hepatic impairment * Hypertension (Stage 1 defined as systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg on 2 of 3 measurements at least 15 min apart at initial screening; systolic blood pressure \>155 mmHg or diastolic blood pressure \>99 mmHg on 2 of 3 measurements at least 15 min apart during infusion visits) * Heart rate \<50 bpm or \>150 bpm at initial screening * Chronic congestive heart failure, tachyarrhythmias, myocardial ischemia assessed via EKG at initial screening * EKG QTcF intervals \>430 ms for men and \>470 ms for women * Direct physical access to or routine handling of addicting drugs in the regular course of work duties * MRI contraindication * Pregnant or nursing females

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • Stanford Psychiatry

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.